Editors at The Lancet Rheumatology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from disorders of the immune system to sex and gender in research design, the transitional care for adolescent patients with rheumatic diseases to care for undocumented immigrants, and more.
The Lancet Rheumatology in conversation with
Claim This Podcastby The Lancet Group
3.5(2 reviews)
38 episodes
Updated Bi-weekly
Accepts GuestsHas SponsorsLocation 🇬🇧
61
Podcast Authority
BetaGoodBased on show quality, social media presence, reviews, charts, and more
Quality34
Social100
YouTube93
Engagement75
Podcast Overview
Editors at The Lancet Rheumatology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from disorders of the immune system to sex and gender in research design, the transitional care for adolescent patients with rheumatic diseases to care for undocumented immigrants, and more.
Language
🇺🇲
Publishing Since
12/22/2021
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
61
Podcast Authority
BetaGoodBased on show quality, social media presence, reviews, charts, and more
Quality34
Social100
YouTube93
Engagement75
8
Excellent Areas
2
Good Performance
9
Growth Opportunities
excellent
Episode Length
14 minutes
Performing excellently!
good
Show Notes Quality
3.0/5
Recommendations available
Unlock the full report to see detailed tips
poor
Publishing Consistency
Every 49 days
Recommendations available
Unlock the full report to see detailed tips
+16 More Metrics
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
What's Included in Your Full Report
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
Get your free podcast insights report
See how your show performs across every key metric
Instant delivery
No spam
Attract Better Guests
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Secure Sponsorships
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Grow Your Audience
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
1 verified contact email on file for The Lancet Rheumatology in conversation with
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
July 21, 2026
Mrinalini Dey on the association between health literacy and outcomes in people with inflammatory arthritis
In August’s episode, Dr Mrinalini Dey from the Centre for Rheumatic Diseases at King’s College London discusses her recent publication on the association between health literacy and outcomes in people with inflammatory arthritis in England. Health literacy—the ability to access, understand, evaluate, and use health information and services in ways that promote and maintain good health and wellbeing—is increasingly recognised as a key factor in promoting health and managing chronic diseases.The World Health Organization has identified health literacy as central to the prevention and control of non-communicable diseases, such as rheumatic and musculoskeletal conditions. As a potentially modifiable social determinant of health, health literacy can influence how patients experience and manage disease. Yet, its relationship with clinical outcomes, mental health, work participation, and broader social factors in inflammatory arthritis remains poorly understood. We discuss the findings from Dr Dey’s large, national cohort study, how we can improve health literacy disparities in patients, and what should be next on the research agenda to tackle this issue. Click here to read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(26)00081-0/fulltext
June 22, 2026
Enpatoran for Cutaneous or Systemic Lupus with Eric Morand
In today’s episode Professor Eric Morand discusses the results of Cohort A and Cohort B of the WILLOW trial which investigated the efficacy and safety of enpatoran, a novel, oral small molecule inhibitor of Toll-like receptors 7 and 8 (TLR 7/8) in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE). The interferon pathway has been implicated in both CLE and SLE pathogenesis, however, the mechanism through which interferon expression is induced in lupus remains unknown. Targeting TLR 7/8 is of particular interest, as they are key drivers of interferon activation. Enpatoran has previously shown efficacy in early phase 1 trials of patients with CLE and SLE, with improvements in SLEDAI-2K and reduction in IFN-gene signatures with good safety profiles. We also highlight the differences in study design and endpoints of each cohort, compare and contrast enpatoran to currently approved therapies for SLE, anifrolumab and deucravacitinib, and finally, outline what the next research priority should be for patients with CLE and SLE. Click here to read the full articles: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00337-6/fulltext and https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00463-0/fulltext
May 25, 2026
Tue Wenzel Kragstrup on GLP-1 and DPP-4 in the synovial fluid of patients with rheumatic disease
In this month’s podcast, we explore Associate Professor Kragstrup’s recent proof-of-concept study which reports glucagon-like peptide-1 (GLP-1) concentrations and dipeptidyl peptidase-4 (DPP-4) activity in paired plasma and synovial fluid from patients with rheumatoid arthritis and spondyloarthritis and discuss whether there may be potential for intra-articular GLP-1 receptor agonist injections in these patients? GLP-1 receptor agonists are gaining increasing attention in rheumatology due to their immunomodulatory and anti-inflammatory effects, highlighting their role as a potential therapeutic option for patients with rheumatic disease. Whether GLP-1 and DPP-4 (the key regulator of GLP-1) are present in synovial fluid of patients with rheumatic disease and to what extent remains to be seen. Understanding their interplay within the joint may provide more insight on whether GLP-1 receptor agonists could exert direct intra-articular effects in rheumatic disease. We also discuss limitations and barriers of investigating GLP-1 and DPP-4 and the next research priorities for determining the efficacy of GLP-1 receptor agonists in patients with rheumatic disease. Click here to read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(26)00074-3/fulltext
38 total episodes available
Recent guests on The Lancet Rheumatology in conversation with
Guests from recent episodes — sign up to see every guest that has ever appeared on this show.
Xue Li
Guest
Sinisa Savic
Guest
Fabian Müller
Guest
Melanie Hagen
Guest
Similar Podcasts
Discover related shows you might enjoy
The Evidence Based Rheumatology Podcast
Michael Putman
ACR Journals On Air
American College of Rheumatology
ACR on Air
American College of Rheumatology
Rheumnow Podcast
Dr. Cush
Healio Rheuminations
Adam J. Brown, MD
Rheumatology For The Royal College
Dr. Karim Ladak
Around the Rheum
Canadian Rheumatology Association
The Evidence Based Rheumatology Podcast
Michael Putman
IMID Rheumatology
The Immune-Mediated Inflammatory Disease Forum
JAMA Medical News
JAMA Network
NEJM This Week
NEJM Group
The Curbsiders Internal Medicine Podcast
The Curbsiders Internal Medicine Podcast
The Daily
The New York Times
Deep-dive analytics for The Lancet Rheumatology in conversation with
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is The Lancet Rheumatology in conversation with?
- How often does this podcast release new episodes?
This podcast updates bi-weekly.
- Where can I listen to this podcast?
This podcast is available on 10 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.